Colorescience Launches Sunstoppable™ Program to Change the Sun Protection Habits of Current and Future Generations
May 6, 2015Colorescience launches Sunstoppable, a program that aims to educate current and future generations about the importance of proper suncare year-round.
More »
Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1)
May 6, 2015Dicerna presents preclinical data demonstrating the feasibility of its DsiRNA-EX Conjugate-mediated delivery technology in enabling direct delivery of its RNAi-based investigational therapy to the liver at the 17th Annual TIDES in San Diego.
More »
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
May 6, 2015CoLucid, the Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announces the pricing of 5,500,000 shares of common stock at $10.00 per share.
More »